A major data-manipulation scandal has rocked Novartis. Here's everything we learned from a new 59-page letter the Swiss drug giant sent to its regulators.

A data-manipulation scandal has rocked Swiss drug giant Novartis and its new rare-disease treatment Zolgensma. A clearer picture is now emerging with a new59-page letter…

Read More A major data-manipulation scandal has rocked Novartis. Here's everything we learned from a new 59-page letter the Swiss drug giant sent to its regulators.